Abstracts tagged "fibromyalgia"

Abstract Number: 2308 • 2015 ACR/ARHP Annual Meeting
Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)
R Michael Gendreau¹, Daniel J. Clauw², Judith Gendreau³, Bruce Daugherty³ and Seth Lederman⁴, ¹Gendreau Consulting LLC, Poway, CA, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³Tonix Pharmaceuticals, New York, NY, ⁴Research and Development, Tonix Pharmaceuticals, Inc., New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by symptoms that include widespread pain and sleep disruption. Clinical studies that rely on patient self-reported outcome measures such as pain…
Abstract Number: 1090 • 2015 ACR/ARHP Annual Meeting
Characteristics and Trajectories of Child Pain, Function, and Psychological Outcomes Associated with Conversion Disorder in Intensive Interdisciplinary Pediatric Pain Rehabilitation
Cara Hoffart¹ and Dustin Wallace², ¹Rheumatology and Integrative Pain Management, Children's Mercy Hospital, Kansas City, MO, ²Integrative Pain Management and Developmental and Behavioral, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Given the degree of compromise in quality of life, there is a critical need to identify the natural history of pain and disability in…
Abstract Number: 2309 • 2015 ACR/ARHP Annual Meeting
Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study
Seth Lederman¹, R Michael Gendreau², Daniel J. Clauw³, Lesley M. Arnold⁴, Judith Gendreau⁵, Bruce Daugherty⁵ and Amy Forst⁶, ¹Research and Development, Tonix Pharmaceuticals, Inc., New York, NY, ²Gendreau Consulting LLC, Poway, CA, ³Anesthesiology, University of Michigan, Ann Arbor, MI, ⁴Psychiatry, University of Cincinnati, Cincinnati, OH, ⁵Tonix Pharmaceuticals, New York, NY, ⁶Clinical Development, Tonix Pharmaceuticals, San Jose, CA
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and sleep disturbance. Treatments that improve sleep quality in FM patients may improve fibromyalgia by a…
Abstract Number: 1091 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Multidisciplinary Pain Rehabilitation Programs for Patients with Fibromyalgia Syndrome: A Systematic Review
Niall Halliday^1,2, Caroline Treanor², Rose Galvin³ and Jason Brooks⁴, ¹Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, Northern Ireland, ²Physiotherapy, Beaumont Hospital, Dublin, Ireland, ³Clinical Therapies, University of Limerick, Limerick, Ireland, ⁴Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, Ireland
Background/Purpose: Fibromyalgia syndrome (FMS) is a common, chronic pain condition with complex multiple symptoms. Combinations of therapies in a multidisciplinary pain rehabilitation program (MPRP) are…
Abstract Number: 2310 • 2015 ACR/ARHP Annual Meeting
Evaluation of Fibromyalgia Syndrome in Patients Undergoing Peritoneal Dialysis
Taskin Senturk¹, Gokhan Sargin² and Hakan Akdam³, ¹Rheumatology, Adnan Menderes University School of Medicine, Aydin, Turkey, ²Rheumatology, Adnan Menderes University Rheumatology, Aydin, Turkey, ³Nephrology, Adnan Menderes University, Nephrology, Aydin, Turkey
Background/Purpose: Fibromyalgia syndrome (FMS) is characterized by widespread pain, fatigue, memory problems. The syndrome is present in about %2-8 of general population. However, knowledge about this…
Abstract Number: 1427 • 2015 ACR/ARHP Annual Meeting
Analgesic Effects of the Novel Alpha-2-Delta Ligand Mirogabalin (DS-5565) in Experimental Animal Models of Fibromyalgia
Yuki Domon¹, Naohisa Arakawa¹, Shun-ichi Yasuda², Kensuke Saeki², Mayumi Kano², Masami Kato² and Yutaka Kitano¹, ¹Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan, ²Hashima Laboratory, Nihon Bioresearch Inc., Gifu, Japan
Background/Purpose: Mirogabalin (DS-5565) is a novel ligand of the α2δ subunit of voltage-gated calcium channels. Mirogabalin possesses unique binding characteristics to α2δ subunits, and potent…
Abstract Number: 2311 • 2015 ACR/ARHP Annual Meeting
Safety of Pregabalin for Treatment of Fibromyalgia Is Comparable Between Subjects with Moderate or Severe Baseline Widespread Pain
Andrew Clair¹ and Birol Emir², ¹Pfizer Inc, New York, NY, ²Primary Care Business Unit, Pfizer Global Research and Development, New York, NY
Background/Purpose: Pregabalin has demonstrated efficacy and safety for the treatment of pain associated with fibromyalgia (FM) and is approved by the US Food and Drug…
Abstract Number: 1443 • 2015 ACR/ARHP Annual Meeting
A Multiple Ascending-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirogabalin in Healthy Elderly Subjects
Karen Brown¹, Yoshihiro Kumagae¹, Shoichi Ohwada², Vance Warren¹, Hamim Zahir¹ and Victor Dishy¹, ¹Daiichi Sankyo Pharma Development, Edison, NJ, ²Daiichi Sankyo Co., Ltd., Tokyo, Japan
Background/Purpose: Mirogabalin (DS-5565) is a preferentially selective a2d-1 ligand intended for treatment of pain associated with fibromyalgia and neuropathic pain. We evaluated the safety, tolerability,…
Abstract Number: 2325 • 2015 ACR/ARHP Annual Meeting
Quantitative Clues to Recognize and Document Comorbid Fibromyalgia in Routine Care of Patients with Other Rheumatic Diagnoses on a 10 Cm Distress Visual Analog Scale Found on 1-Page Physician Rheumetric Checklist
Kathryn A. Gibson¹, Katherine J. Bryant² and Theodore Pincus³, ¹Liverpool Hospital, Liverpool, Australia, ²University of New South Wales, Sydney, Australia, ³Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: A physician global estimate (DOCGL) is commonly used to assess patients with rheumatic diseases. Fibromyalgia (FM) has been reported as a comorbidity in 10-35%…
Abstract Number: 1467 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life Is Reduced in Pediatric Patients with Juvenile Idiopathic Arthritis and Juvenile-Onset Fibromyalgia
Michal Feldon¹, Catherine Donnelly², Hermine I. Brunner³, Anne Louis Johnson¹, Lukasz Itert⁴, Lisa G Rider⁵ and Edward H. Giannini³, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Internal Medicine, University of Cincinnati, Cincinnati, OH, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD
Background/Purpose : A number of validated measures are now available for the evaluation of health related quality of life (HRQOL) in children with rheumatic diseases,…
Abstract Number: 2335 • 2015 ACR/ARHP Annual Meeting
How Much Does Fatigue Contribute to the Physician and Patient Global Estimates in Different Rheumatic Diseases? Analysis from Routine Care on a Multidimensional Health Assessment Questionnaire (MDHAQ)
Isabel Castrejón¹, Elena Nikiphorou², Ruchi Jain¹, Annie Huang¹, Joel A. Block³ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Fatigue is an important problem for many patients with rheumatic diseases. Fatigue is associated with disease severity, psychological distress, and a poorer quality of…
Abstract Number: 1469 • 2015 ACR/ARHP Annual Meeting
A Comparison of Pain and Disability, and Their Association Between Juvenile Primary Fibromyalgia Syndrome and Pediatric Rheumatic Diseases: Results from the Childhood Arthritis and Rheumatology Research Alliance Registry
Jennifer E. Weiss¹ and Mark Connelly², ¹Hackensack Univ Med Ctr, Hackensack, NJ, ²Psychology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: We aim to determine the extent to which pain severity differs between patients with JPFS and other rheumatic diseases and if the degree of…
Abstract Number: 2475 • 2015 ACR/ARHP Annual Meeting
Association Between Fibromyalgia and Suicidal Risk: A Systematic Review and Meta-Analysis
Sikarin Upala¹ and Anawin Sanguankeo², ¹Internal Medicine, Bassett Medical Center, Cooperstown, NY, ²Bassett Medical Center, Cooperstown, NY
Background/Purpose: Chronic pain conditions are related poor overall health, economic burden, and mental disorders including suicidal ideation (SI), suicide attempts (SA), and completed suicides. Fibromyalgia…
Abstract Number: 2287 • 2015 ACR/ARHP Annual Meeting
Evaluation of the Fibromyalgia Rapid Screening Tool (FiRST) Questionnaire to Screen Fibromyalgia Associated with Inflammatory Rheumatic Disease
Angélique Fan¹, Bruno Pereira², Anne Tournadre³, Zuzana Tatar¹, Sandrine Malochet-Guinamand⁴, Martin Soubrier¹ and Jean-Jacques Dubost¹, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ³Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁴Rheumatology Department,, Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Fibromyalgia (FM) is prevalent in patients with chronic inflammatory rheumatic diseases (CIRd), where it hampers diagnosis and activity assessment. No tool for screening FM…
Abstract Number: 2697 • 2015 ACR/ARHP Annual Meeting
Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia
Jayanth Doss¹, Huan Mo², Leslie J. Crofford¹ and Joshua C. Denny², ¹Rheumatology, Vanderbilt University School of Medicine, Nashville, TN, ²Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN
Background/Purpose: The differences between seronegative and seropositive rheumatoid arthritis (RA) have not been widely reported. We performed an electronic health record (EHR)-based phenome-wide association study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].